Læknablaðið - 15.11.2011, Blaðsíða 39

Y F I R L I T
35. Otto MW, Behar E, Smits JAJ, Hofmann SG. Combining
pharmacological and cognitive behavioral therapy in the
treatment of anxiety disorders. In: Antony MM, Stein MB,
ed. Oxford Handbook of Anxiety and Related Disorders.
Oxford University Press, New York 2009:429-41.
36. Bisson J, Andrew M. Psychological treatment of post-
traumatic stress disorder (PTSD). Cochrane Database Syst
Rev 2007; 3: CD003388.
37. National Institute for Clinical Exellence. Post-traumatic
stress disorder (PTSD): The management of PTSD in adults
and children in primary and secondary care. Clinical
guideline 26. NICE, London 2005.
38. Riggs DS, Foa EB. Psychological treatment of posttraumatic
stress disorder and acute stress disorder. In: Antony MM,
Stein MB, ed. Oxford Handbook of Anxiety and Related
Disorders. Oxford University Press, New York 2009: 417-
29.
39. Frommberger U, Stieglitz RD, Nyberg E, et al. Comparison
between paroxetine and behaviour therapy in patients
with posttraumatic stress disorder (PTSD): A pilot study.
Int J Psychiatr Clin Pract 2004; 8:19-23.
40. Powers MB, Halpem JM, Ferenschak MP, Gillihan SJ, Foa
EB. A meta-analytic review of prolonged exposure for
ptsd. Clin Psychol Rev 2010; 30: 635-41.
41. Penava SJ, Otto MW, Pollack MH, Rosenbaum JF. Current
status of pharmacotherapy for PTSD: an effect size analysis
of controlled studies. Depress Anxiety 1996; 4: 240-2.
42. Foa EB, Hembree EA, Cahill SP, et al. Randomized trial of
prolonged exposure for posttraumatic stress disorder wit
and without cognitive restructuring: outcome at academic
and community clinics. J Consult Clin Psychol 2005; 73:
953-64.
43. Hetrick SE, Purcell R, Gamer B, Parslow R. Combined
pharmacotherapy and psychological therapies for post
traumatic stress disorder (PTSD). Cochrane Database Syst
Rev 2010; 7: CD007316.
44. Clark DA. Cognitive-behavioral Therapy for OCD.
Guilford, New York 2004.
45. National Institute for Clinical Exellence. Core interventions
in the treatment of obsessive-compulsive disorder and
body dysmorphic disorder. Clinical guidelines 31. NICE,
London 2005.
46. Simpson, HB, Liebowitz MR, Foa EB, et al. Post-treatment
effects of exposure therapy and clomipramine in obsessive
compulsive disorder. Depress Anxiety 2004; 19: 225-33.
47. Foa EB, Kozak MJ. Psycholocial treatments for obsessive-
compulsive disorder. In: Mavissakalian MR, Prien RF, ed.
Long-term Treatments of Anxiety Disorders. American
Psychiatric Press, Washington DC 1996: 285-309.
48. Foa EB, Franklin ME, Moser J. Context in the clinic: How
well do cognitive-behavioral therapies and medications
work in combination? Biol Psychiatry 2002; 52: 987-97.
49. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized,
placebo-controlled trial of exposure and ritual prevention,
clomipramine, and their combination in the treatment of
obsessive-compulsive disorder. Am J Psychiatry 2005; 162:
151-61.
50. Franklin ME. Meeting in the middle, then moving forward
together. In Abramowitz JS, Houts AC, ed. Concepts
and Controversies in Obsessive Compulsive Disorder.
Springer, New York 2005: 395-400.
51. Gould RA, Buckminster S, Pollack MH, Otto MW, Yap
L. Cognitive-behavioral and pharmacological treatment
for social phobia: A meta-analysis. Clin Psychol: Sci Pract
1997; 4: 291-306.
52. Clark DM, Ehlers A, McManus F, et al. Cogntive
therapy versus fluoxetine in generalized social phoba:
A randomized placebo-controlled trial. J Consult Clin
Psychol 2003; 71:1058-67.
53. Magee L, Erwin B, Heimberg R. Psychological treatment
of social anxiety disorder and specific phobia. In: Antony
MM, Stein MB, ed. Oxford Handbook of Anxiety and
Related Disorders. Oxford University Press, New York
2009: 334-50.
54. Davidson JRT, Foa EB, Hubbert JD, et al. Fluoxetin,
comprehensive cognitive behavioral therapy, and placebo
in generalized social phobia. Arch Gen Psychiatry 2004; 61:
1005-13.
55. Antony MM, Barlow DH. Specific phobia. In: Barlow DH,
ed. Anxiety and Its Disorders. 2nd ed. Guilford, New York
2002: 380-418.
56. Van Ameringen M, Mancini C, Patterson B.
Pharmacotherapy for social anxiety and specific phobia.
In: Antony MM, Stein MJ, ed. Oxford Handbook of
Anxiety and Related Disorders. Oxford University Press,
New York 2009: 321-34.
57. Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ.
Psychological approaches in the treatment of specific
phobias: A meta analysis. Clin Psychol Rev 2008; 28:1021-
37.
58. Brown TA, Campell LA, Lehman CL, Grisham JR, Mancill
RB. Current and lifetime comorbidity of the DSM-IV
anxiety and mood disorders in a large clinical sample. J
Abnorm Psychol 2001; 110: 585-99.
59. Fava M, Rush AJ, Alpert JE, et.al. Difference in treatment
outcome in outpaitents with anxious versus nonanxious
depression: A STAR*D Report. Am J Psychiatry 2008; 165:
342-51.
60. McEvoy PM, Nathan P. Effectiveness of cognitive behavior
therapy for diagnostically heterogeneous groups: a
benchmarking study. J Consult Clin Psychol. 2007; 75: 344-
50.
61. Morrison N. Group cognitive therapy: treatment of choice
or sub-optimal option? Behav Cogn Psychother 2001; 29:
311-32.
Urðarapótek
er íviðskiptum
hjá okkur
Guðrún Pálsdóttir stofnaði Urðarapótek
og keppir við þá stóru á markaðnum
með áherslu á góð kjör og betri þjónustu.
Við þekkjum slíkar aðstæður mjög vel.
Þess vegna er Urðarapótek í viðskiptum
hjá okkur.
BANKI
Ármúla 13a | Borgartúni 26 1540 3200 | www.mp.is
LÆKNAblaðið 2011/97 619